WuXi XDC and HKSTP Partner to Foster Growth in Hong Kong Bioconjugate Drug Sector

WuXi XDC, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in the field of Antibody-Drug Conjugates (ADC) and the broader bioconjugate market, has recently entered into a collaborative agreement with the Hong Kong Science and Technology Parks Corporation (HKSTP). This partnership aims to jointly advance the establishment of a comprehensive CRDMO value chain in Hong Kong.

This collaboration is intended to drive the development of ADCs and other bioconjugates in Hong Kong, utilizing WuXi XDC's extensive range of services and capabilities. The primary objective is to strengthen the biotechnology ecosystem in Hong Kong by fostering closer collaboration among industry players, academic institutions, and research organizations.

Under this agreement, companies within the HKSTP Park ecosystem will gain access to WuXi XDC's integrated platform, providing a one-stop solution for bioconjugate-based drug discovery, development, and analytical services. Additionally, WuXi XDC will offer consultation and training to biotechnology companies and research institutions in Hong Kong to expedite the transformation of scientific research findings into market-ready products.

Furthermore, HKSTP and WuXi XDC will deepen their collaboration by pooling resources and organizing joint activities. Together, they will outline a strategic roadmap to accelerate the establishment of a CRDMO value chain in Hong Kong. This, in turn, will streamline the drug development process and reduce the time required to bring innovative pharmaceutical products to market.

"We are delighted to partner with HKSTP to offer our one-stop platform, extensive industry expertise, and high-quality services to support local biotech firms. Hong Kong Science Park boasts a strong foundation in biotechnology with a focus on innovation. We are eager to solidify our partnership with HKSTP to drive the growth of the bioconjugate industry, ultimately benefiting patients worldwide."

"As the largest hub for technology research and development (R&D) and incubation in Hong Kong, HKSTP provides comprehensive state-of-the-art infrastructure and support services to the Innovation and Technology (I&T) ecosystem. We are excited to collaborate with WuXi XDC in assisting companies with technology transfer and expanding their market reach. By harnessing the strengths of both parties, we are committed to further enhancing the biotechnology ecosystem, positioning Hong Kong as a global hub for innovation and technology."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!